Sodium‐glucose co‐transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials

Many patients with type 1 diabetes (T1D) struggle to achieve glycaemic control and experience significant fluctuations in glucose concentrations, despite insulin treatment. Sodium‐glucose co‐transporter (SGLT)‐2 inhibitors and dual SGLT‐1/2 inhibitors increase glucose elimination via the kidneys and...

Descripción completa

Detalles Bibliográficos
Autores principales: Boeder, Schafer, Edelman, Steven V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
An Overview of Therapeutic Developments Which Target The Sodium‐Glucose Co‐Transporter Proteins. Publication of this supplement has been made possible by unrestricted educational grants from Sanofi US and Boehringer Ingelheim (South Korea)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899736/
https://www.ncbi.nlm.nih.gov/pubmed/31081593
http://dx.doi.org/10.1111/dom.13749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899736/
https://www.ncbi.nlm.nih.gov/pubmed/31081593
http://dx.doi.org/10.1111/dom.13749

Ejemplares similares